Asset profile
ketamine · NRX Pharmaceuticals (NRXP)
- Indication
- suicidal ideation in depression, including bipolar depression
- Also known as
- KETAFREE™, preservative free ketamine, NRX-100, preservative-free intravenous ketamine
Company
NRXPNRX Pharmaceuticals
NRXPNRX PharmaceuticalsNRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing…
On the calendar
10
Aug 2026
Aug 10, 2026
82 days ago
NRXPNRX Pharmaceuticals10
Nov 2026
Nov 10, 2026
in 10 days
NRXPNRX PharmaceuticalsTimeline
Newest first.
Sep 16, 2026
01:17 AM
NRXPNRX PharmaceuticalsAug 17, 2026
12:00 PM
NRXPNRX PharmaceuticalsAug 7, 2026
08:01 PM
NRXPNRX PharmaceuticalsNRx Pharmaceuticals to host FDA ANDA review call August 10
Aug 7, 2026
11:00 AM
NRXPNRX PharmaceuticalsFeb 17, 2026
02:21 PM
NRXPNRX PharmaceuticalsSep 26, 2025
12:01 PM
NRXPNRX PharmaceuticalsNRXP: FDA grants Suitability Petition for KETAFREE™ preservative-free ketamine
Registered trials
| Registry ID | Phase | Status | Primary completion | Enrollment | Sites |
|---|---|---|---|---|---|
| NCT04260607 | Phase 3 | Terminated | Apr 24, 2021 | 1 | 1 of 1 sites in the United States |
| NCT05674877 | Phase 3 | Completed | Jun 28, 2023 | 100 | 0 of 1 sites in the United States |
| NCT07716098 | Phase 3 | Recruiting | Dec 27, 2028 | 348 | 7 of 22 sites in the United States |
| NCT02487485 | Phase 2 | Completed | Jan 1, 2020 | 23 | 2 of 2 sites in the United States |
| NCT06713616 | Phase 3 | Recruiting | Dec 31, 2030 | 400 | 8 of 8 sites in the United States |
| NCT03448068 | Phase 2 | Completed | Jan 9, 2020 | 34 | 1 of 1 sites in the United States |
| NCT02521415 | Phase 2 | Completed | Nov 1, 2016 | 87 | 1 of 1 sites in the United States |
| NCT02857361 | Phase 2 | Completed | Aug 1, 2016 | 10 | 0 of 1 sites in the United States |